Imipenem

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Image:Imipenem.svg
Imipenem
Systematic (IUPAC) name
(5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-
6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-
2-ene-2-carboxylic acid
Identifiers
CAS number 74431-23-5
ATC code J01DH51
PubChem 47317
Chemical data
Formula C12H17N3O4S 
Mol. mass 299.347 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism Renal
Half life 60 minutes
Excretion  ?
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status
Routes IM, IV

WikiDoc Resources for

Imipenem

Articles

Most recent articles on Imipenem

Most cited articles on Imipenem

Review articles on Imipenem

Articles on Imipenem in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Imipenem

Images of Imipenem

Photos of Imipenem

Podcasts & MP3s on Imipenem

Videos on Imipenem

Evidence Based Medicine

Cochrane Collaboration on Imipenem

Bandolier on Imipenem

TRIP on Imipenem

Clinical Trials

Ongoing Trials on Imipenem at Clinical Trials.gov

Trial results on Imipenem

Clinical Trials on Imipenem at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Imipenem

NICE Guidance on Imipenem

NHS PRODIGY Guidance

FDA on Imipenem

CDC on Imipenem

Books

Books on Imipenem

News

Imipenem in the news

Be alerted to news on Imipenem

News trends on Imipenem

Commentary

Blogs on Imipenem

Definitions

Definitions of Imipenem

Patient Resources / Community

Patient resources on Imipenem

Discussion groups on Imipenem

Patient Handouts on Imipenem

Directions to Hospitals Treating Imipenem

Risk calculators and risk factors for Imipenem

Healthcare Provider Resources

Symptoms of Imipenem

Causes & Risk Factors for Imipenem

Diagnostic studies for Imipenem

Treatment of Imipenem

Continuing Medical Education (CME)

CME Programs on Imipenem

International

Imipenem en Espanol

Imipenem en Francais

Businness

Imipenem in the Marketplace

Patents on Imipenem

Experimental / Informatics

List of terms related to Imipenem

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Imipenem is an intravenous beta-lactam antibiotic developed in 1985. Imipenem belongs to the subgroup of carbapenems. It is derived from a compound called thienamycin, which is produced by the bacteria Streptomyces cattleya. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. It is not active against methicillin-resistant Staphylococcus aureus, however. Imipenem and other drugs in the carbapenem class are commonly referred to as "magic bullets." Their use is typically restricted in order to avoid widespread bacterial resistance.

Method of action

Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various gram-positive and gram-negative bacteria. It remains very stable in the presence of beta-lactamase (both penicillinase and cephalosporinase) produced by some bacteria, and is a strong inhibitor of beta-lactamases from some gram-negative bacteria that are resistant to most beta-lactam antibiotics.

Co-administration with cilastatin

Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation.

Adverse effects

Common adverse drug reactions are nausea and vomiting. People who are allergic to penicillin and other beta-lactam antibiotics should not take imipenem. Imipenem can also cause seizures.

References

^  Clissold SP, Todd PA, Campoli Richards DM. Imipenem/Cilastatin: A reivew of its anti-bacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987; 33: 183-241.

See also

de:Imipenem vi:Imipenem

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools